01771nam 2200433Ia 450 991069334200332120050808090348.0(CKB)5470000002362116(OCoLC)61224223(EXLCZ)99547000000236211620050808d2005 ua 0engurmn|---|||||txtrdacontentcrdamediacrrdacarrierMedicaid drug rebate program[electronic resource] inadequate oversight raises concerns about rebates paid to states : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives /statement of Kathleen King[Washington, D.C.] :U.S. Government Accountability Office,[2005]Testimony ;GAO-05-850 TTitle from title screen (viewed on July 27, 2005)."For release ... June 22, 2005."Paper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.Includes bibliographical references.Medicaid drug rebate program MedicaidDrugsPricesUnited StatesStatesPrescription pricingUnited StatesStatesMedicaid.DrugsPricesStates.Prescription pricingStates.King Kathleen1382817United States.Congress.House.Committee on Energy and Commerce.Subcommittee on Health.United States.Government Accountability Office.GPOGPOBOOK9910693342003321Medicaid drug rebate program3426833UNINA